Metsera, Inc. (NASDAQ:MTSR - Get Free Report) fell 7.6% during trading on Monday . The stock traded as low as $23.55 and last traded at $23.70. 169,960 shares were traded during mid-day trading, a decline of 80% from the average session volume of 866,117 shares. The stock had previously closed at $25.65.
Analyst Upgrades and Downgrades
MTSR has been the subject of a number of analyst reports. Cantor Fitzgerald initiated coverage on Metsera in a research note on Tuesday, February 25th. They issued an "overweight" rating for the company. Bank of America started coverage on shares of Metsera in a research note on Tuesday, February 25th. They set a "buy" rating and a $38.00 price target on the stock. Guggenheim assumed coverage on shares of Metsera in a research note on Tuesday, February 25th. They issued a "buy" rating and a $56.00 target price for the company. Finally, Evercore ISI started coverage on Metsera in a research note on Tuesday, February 25th. They issued an "outperform" rating for the company.
Read Our Latest Research Report on Metsera
Metsera Trading Up 5.6 %
The stock has a 50 day moving average of $22.95.
Metsera (NASDAQ:MTSR - Get Free Report) last issued its quarterly earnings data on Wednesday, March 26th. The company reported ($3.52) earnings per share (EPS) for the quarter.
Institutional Trading of Metsera
Institutional investors have recently modified their holdings of the company. New York State Common Retirement Fund bought a new stake in Metsera during the first quarter worth approximately $131,000. Bank of New York Mellon Corp acquired a new position in Metsera in the 1st quarter worth approximately $884,000. TD Asset Management Inc purchased a new position in Metsera during the 1st quarter worth approximately $2,091,000. Jennison Associates LLC purchased a new stake in shares of Metsera in the first quarter valued at $9,679,000. Finally, Massachusetts Financial Services Co. MA acquired a new stake in shares of Metsera in the first quarter worth $13,111,000.
Metsera Company Profile
(
Get Free Report)
Metsera, Inc is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o.
Recommended Stories
Before you consider Metsera, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Metsera wasn't on the list.
While Metsera currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
